As per the alliance, the high-level cancer research technology and clinical experience of the National Cancer Center will be integrated with the advanced research and drug discovery capabilities of Daiichi Sankyo.
The National Cancer Center will present Daiichi Sankyo with research results in line with Daiichi Sankyo’s research and drug discovery policy and promote "Exploratory Research for Drug Target Identification or "Early Drug Discovery Research".
The Exploratory Research for Drug Target Identification will include exploration, identification, and evaluation of drug targets.
Under the Early Drug Discovery Research, Daiichi Sankyo will work to acquire drug candidate compounds and antibodies through high-throughput screening.